Skip to content
Home/Companies/Biotech/Apmonia Therapeutics
Apmonia Therapeutics

Apmonia Therapeutics

Biotech·France·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Apmonia Therapeutics?

Apmonia Therapeutics is a French Biotech company, currently owned by Finovam Gestion since 2022.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Finovam Gestion
Investor
Finovam Gestion
FIRA · 2015 · VC

Key facts

HQFrance
SectorBiotech
Websiteapmonia-therapeutics.com

More from FIRA

Other portfolio companies in the same fund.

Innobiochips
Innobiochips
Active
MedTechFrance· 2023
Nolej
Nolej
Active
EdTechFrance· 2023
Augmenteo
Exited 2023
GamingFrance· 2020
to Reaali
G-Lyte
Active
ClimateTechFrance· 2020
Retail Shake
Retail Shake
Active
Data & AnalyticsFrance· 2020
Whispeak
Whispeak
Active
CybersecurityFrance· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Apmonia Therapeutics?

Apmonia Therapeutics is currently owned by Finovam Gestion, through FIRA, since 2022.

When did Finovam Gestion acquire Apmonia Therapeutics?

Finovam Gestion acquired Apmonia Therapeutics in 2022.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue